Durability of Immunity and Safety of RSV Vaccination in High-Risk Transplant Recipients

Victoria G. Hall; Adrian A Alexander; Madeline R. Kern-Smith; Faranak Mavandadnejad; Sarayna Bala; Xiaoqing Dang; Rujun Kang; Sapna S. Humar; Poramed Winichakoon; Rochelle Johnstone; Ailya Salman; Meghan M. Aversa; Igor Novitzky‐Basso; Roni Bitterman; Pascal M. Lavoie; Deepali Kumar; Jonas Mattsson; Victor H. Ferreira

doi:10.1001/jamanetworkopen.2026.41946

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

This nonrandomized clinical trial examines humoral and cell-mediated immunity and longer-term safety following vaccination for respiratory syncytial virus (RSV) among recipients of lung transplant and allogeneic hematopoietic cell transplant.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hall et al. (2026) studied this question.

synapsesocial.com/papers/6af0110ec0da893a53643287 https://doi.org/10.1001/jamanetworkopen.2026.41946

View Full Paper

Ask AI

Bookmark

Share

Durability of Immunity and Safety of RSV Vaccination in High-Risk Transplant Recipients

Ask about this paper

Abstract

Discussion

Cite This Study

Durability of Immunity and Safety of RSV Vaccination in High-Risk Transplant Recipients

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading